Search Results for "treatment guidelines"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for treatment guidelines. Results 291 to 300 of 432 total matches.

Mepolizumab (Nucala) for Severe Eosinophilic Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
Chung et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma ...
The FDA has approved mepolizumab (Nucala - GSK), a subcutaneously injected humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for maintenance treatment of severe asthma in patients ≥12 years old who have an eosinophilic phenotype.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):11-2 |  Show IntroductionHide Introduction

Vonoprazan (Voquezna) for Nonerosive GERD

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
(Voquezna – Phathom), which was approved earlier for treatment of erosive esophagitis, has now ...
The potassium-competitive acid blocker vonoprazan (Voquezna – Phathom), which was approved earlier for treatment of erosive esophagitis, has now been approved by the FDA for relief of heartburn associated with nonerosive gastroesophageal reflux disease (GERD) in adults. Vonoprazan is also available copackaged with amoxicillin (Voquezna Dual Pak) and with amoxicillin and clarithromycin (Voquezna Triple Pak) for treatment of Helicobacter pylori infection.
Med Lett Drugs Ther. 2024 Oct 14;66(1713):164-6   doi:10.58347/tml.2024.1713c |  Show IntroductionHide Introduction

Antithrombotic Drugs

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 2014  (Issue 1454)
drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants ...
Antiplatelet drugs are the drugs of choice for prevention and treatment of arterial thrombosis. Anticoagulants are the drugs of choice for prevention and treatment of venous thromboembolism and for prevention of cardioembolic events in patients with atrial fibrillation.
Med Lett Drugs Ther. 2014 Oct 27;56(1454):103-8 |  Show IntroductionHide Introduction

Bedaquiline (Sirturo) for Multidrug-Resistant Tuberculosis

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2013  (Issue 1423)
in addition to other drugs for treatment of adults with multidrug-resistant pulmonary tuberculosis (MDR-TB ...
Bedaquiline (bed ak' wi leen; Sirturo – Janssen), a diarylquinoline antimycobacterial, has been given accelerated approval by the FDA as an orphan drug for use in addition to other drugs for treatment of adults with multidrug-resistant pulmonary tuberculosis (MDR-TB). It is the first drug approved specifically to treat MDR-TB.
Med Lett Drugs Ther. 2013 Aug 19;55(1423):66-8 |  Show IntroductionHide Introduction

Pentamidine Aerosol To Prevent Pneumocystis Carinii Pneumonia

   
The Medical Letter on Drugs and Therapeutics • Oct 06, 1989  (Issue 802)
as 60%. Therefore, the new US Public Health Service guidelines recommend PCP prophylaxis for HIV ...
Pneumocystis carinii pneumonia (PCP) occurs in nearly 80% of patients with the acquired immune deficiency syndrome (AIDS) and is a common cause of morbidity and mortality. Oral trimethoprim-sulfamethoxazole (Bactrim; and others), intravenous isethionate (Pentam 300) and other systemic drugs have been used to prevent PCP, but in AIDS patients, all of these agents can occasionally cause severe adverse effects (Medical Letter, 30:94, 1988). Recently, the US Food and Drug Administration approved marketing of aerosolized pentamidine isethionate (NebuPent - LyphoMed) for this indication. Another...
Med Lett Drugs Ther. 1989 Oct 6;31(802):91-2 |  Show IntroductionHide Introduction

A Fixed-Dose Combination of Ibuprofen and Famotidine (Duexis)

   
The Medical Letter on Drugs and Therapeutics • Oct 31, 2011  (Issue 1376)
for ibuprofen and naproxen are for treatment of osteoarthritis or rheumatoid arthritis; the doses of famotidine ...
The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers. Vimovo, a combination of the NSAID naproxen and the proton pump inhibitor (PPI) esomeprazole, is also approved by the FDA for prevention of NSAID-associated gastric ulcers.
Med Lett Drugs Ther. 2011 Oct 31;53(1376):85-6 |  Show IntroductionHide Introduction

An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
injected, single-dose, prefilled epinephrine syringe (Symjepi – Adamis/Sandoz) for emergency treatment ...
The FDA has approved a manually injected, single-dose, prefilled epinephrine syringe (Symjepi – Adamis/Sandoz) for emergency treatment of anaphylaxis. The new device is approved in 0.3- and 0.15-mg strengths for treatment of patients weighing ≥30 kg and 15 to 30 kg, respectively; only the 0.3-mg strength is currently available. According to Sandoz, Symjepi will be made available first to institutions and later to the retail market.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):25-6 |  Show IntroductionHide Introduction

Caplacizumab (Cablivi) for iTTP

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
exchange and immunosuppressive therapy for treatment of immune-mediated thrombotic thrombocytopenic ...
Caplacizumab-yhdp (Cablivi – Sanofi /Genzyme), a von Willebrand factor-directed antibody fragment, has been approved by the FDA for use in combination with plasma exchange and immunosuppressive therapy for treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP; formerly called acquired thrombotic thrombocytopenic purpura [aTTP]) in adults. It is the first drug to be approved in the US for this indication.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):163-4 |  Show IntroductionHide Introduction

TNF Inhibitors for Crohn's Disease: When, Which, and for How Long

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013  (Issue 1432)
) – are approved by the FDA for treatment of moderately to severely active Crohn’s disease in adults who have had ...
Three tumor necrosis factor (TNF) inhibitors – infliximab (Remicade), adalimumab (Humira), and certolizumab pegol (Cimzia) – are approved by the FDA for treatment of moderately to severely active Crohn’s disease in adults who have had an inadequate response to conventional therapy. Infliximab is also FDA-approved for the same indication in children ≥6 years old and for treatment of fistulas in adults. All 3 TNF inhibitors have been shown to reduce the signs and symptoms of Crohn's disease in clinical trials. They have been associated with adverse effects such as...
Med Lett Drugs Ther. 2013 Dec 23;55(1432):102-3 |  Show IntroductionHide Introduction

Golimumab (Simponi) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Mar 31, 2014  (Issue 1439)
continuous treatment with corticosteroids. Golimumab was approved earlier for treatment of rheumatoid ...
The FDA has approved golimumab (Simponi – Janssen), a fully human monoclonal antibody specific for tumor necrosis factor (TNF) alpha, for induction and maintenance of remission in patients with moderate to severe ulcerative colitis who do not respond to or cannot tolerate other therapies or who require continuous treatment with corticosteroids. Golimumab was approved earlier for treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is the third TNF inhibitor to be approved for use in ulcerative colitis.
Med Lett Drugs Ther. 2014 Mar 31;56(1439):25-6 |  Show IntroductionHide Introduction